AU2014346852A1 - Combinations of checkpoint inhibitors and therapeutics to treat cancer - Google Patents

Combinations of checkpoint inhibitors and therapeutics to treat cancer Download PDF

Info

Publication number
AU2014346852A1
AU2014346852A1 AU2014346852A AU2014346852A AU2014346852A1 AU 2014346852 A1 AU2014346852 A1 AU 2014346852A1 AU 2014346852 A AU2014346852 A AU 2014346852A AU 2014346852 A AU2014346852 A AU 2014346852A AU 2014346852 A1 AU2014346852 A1 AU 2014346852A1
Authority
AU
Australia
Prior art keywords
cancer
tumor
cell
checkpoint inhibitor
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014346852A
Other languages
English (en)
Inventor
Marnix Leo Bosch
James Kelly Ganjei
Linda M. Liau
Linda F. Powers
Robert M. Prins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
REVLMMUNE Inc
Northwest Biotherapeutics LLC
University of California San Diego UCSD
Cognate Bioservices Inc
Original Assignee
REVLMMUNE Inc
Northwest Biotherapeutics LLC
University of California Berkeley
University of California San Diego UCSD
Cognate Bioservices Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by REVLMMUNE Inc, Northwest Biotherapeutics LLC, University of California Berkeley, University of California San Diego UCSD, Cognate Bioservices Inc filed Critical REVLMMUNE Inc
Publication of AU2014346852A1 publication Critical patent/AU2014346852A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2014346852A 2013-11-05 2014-11-05 Combinations of checkpoint inhibitors and therapeutics to treat cancer Abandoned AU2014346852A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361900355P 2013-11-05 2013-11-05
US201361900309P 2013-11-05 2013-11-05
US61/900,309 2013-11-05
US61/900,355 2013-11-05
PCT/US2014/064133 WO2015069770A1 (en) 2013-11-05 2014-11-05 Combinations of checkpoint inhibitors and therapeutics to treat cancer

Publications (1)

Publication Number Publication Date
AU2014346852A1 true AU2014346852A1 (en) 2016-06-16

Family

ID=53042035

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014346852A Abandoned AU2014346852A1 (en) 2013-11-05 2014-11-05 Combinations of checkpoint inhibitors and therapeutics to treat cancer

Country Status (15)

Country Link
US (4) US20150273033A1 (enExample)
EP (2) EP4461372A3 (enExample)
JP (1) JP2016540042A (enExample)
KR (1) KR20160093012A (enExample)
CN (1) CN105828834A (enExample)
AU (1) AU2014346852A1 (enExample)
BR (1) BR112016010224A2 (enExample)
CA (1) CA2929407A1 (enExample)
EA (1) EA201690912A1 (enExample)
ES (1) ES2991853T3 (enExample)
HK (1) HK1232119A1 (enExample)
IL (3) IL318946A (enExample)
MX (2) MX2016005925A (enExample)
PH (1) PH12016500841A1 (enExample)
WO (1) WO2015069770A1 (enExample)

Families Citing this family (191)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250091300A (ko) 2008-12-09 2025-06-20 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
SI3081576T1 (sl) 2013-12-12 2019-12-31 Shanghai Hengrui Pharmaceutical Co., Ltd., Protitelo PD-1, njegov antigen-vezavni fragment in njegova medicinska uporaba
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
US10682400B2 (en) * 2014-04-30 2020-06-16 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
BR112017016973A2 (pt) * 2015-02-09 2018-04-03 Synta Pharmaceuticals Corp. terapia de combinação de inibidores de hsp90 e inibidores de pd-1 para tratamento de câncer
CN112263677A (zh) * 2015-02-26 2021-01-26 默克专利股份公司 用于治疗癌症的pd-1/pd-l1抑制剂
CN107530341B (zh) 2015-03-06 2021-10-01 大连万春布林医药有限公司 治疗与ras突变相关的癌症的方法
EP3268012A4 (en) 2015-03-12 2018-10-31 Health Research, Inc. Enrichment of cd16+ monocytes to improve dendritic cell vaccine quality
SG11201707383PA (en) 2015-03-13 2017-10-30 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
WO2016145578A1 (en) * 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
US20180127717A1 (en) * 2015-05-07 2018-05-10 Baylor College Of Medicine Dendritic cell immunotherapy
SG11201708804WA (en) 2015-05-07 2017-11-29 Agenus Inc Anti-ox40 antibodies and methods of use thereof
US10314854B2 (en) * 2015-05-15 2019-06-11 University Of Iowa Foundation Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy
MX2017015186A (es) 2015-05-28 2018-07-06 Kite Pharma Inc Metodos de acondicionamiento de pacientes para tratamiento con linfocitos t.
US11779601B2 (en) * 2015-05-28 2023-10-10 Kite Pharma, Inc. Diagnostic methods for T cell therapy
JP6792294B2 (ja) * 2015-05-29 2020-11-25 ダイナバックス テクノロジーズ コーポレイション 肺のがんを処置するためのポリヌクレオチドのＴｏｌｌ様受容体９アゴニストの肺内投与
MA44594B1 (fr) 2015-05-29 2020-09-30 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
EP4541361A3 (en) * 2015-06-01 2025-07-30 The University of Chicago Treatment of cancer by manipulation of commensal microflora
MX390878B (es) 2015-06-16 2025-03-21 Merck Patent Gmbh Usos medicos de antagonista de ligando 1 de muerte programada (pd-l1).
BR112017028530A2 (pt) * 2015-07-02 2018-08-28 Celgene Corp terapia combinada para tratamento de cânceres hematológicos e tumores sólidos
DK3334726T3 (da) 2015-07-13 2022-05-16 Beyondspring Pharmaceuticals Inc Plinabulinsammensætninger
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
CN116196426A (zh) 2015-07-16 2023-06-02 百欧肯治疗有限公司 治疗癌症的组合物及方法
RU2711380C2 (ru) * 2015-07-16 2020-01-16 Байоксэл Терапьютикс, Инк. Новый подход к лечению рака с применением иммуномодуляции
KR102666477B1 (ko) 2015-07-31 2024-05-17 더 존스 홉킨스 유니버시티 글루타민 유사체의 프로드럭
US10842763B2 (en) 2015-07-31 2020-11-24 The Johns Hopkins University Methods for cancer and immunotherapy using prodrugs of glutamine analogs
CN108135875B (zh) 2015-07-31 2021-12-31 约翰霍普金斯大学 用于治疗代谢重编程病症的方法和组合物
DK3139170T3 (en) * 2015-08-10 2019-01-28 Univ Medical Hospital China PROCEDURE FOR ASSESSING IF A PATIENT WITH GLIOBLASTOMA MULTIFORM IS SUITABLE FOR IMMUNTERY TREATMENT BASED ON DENDRITIC CELL TUMOR VACCINES
WO2017040790A1 (en) 2015-09-01 2017-03-09 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
DK3349731T3 (da) * 2015-09-16 2024-01-08 Univ Texas Kombination af topoisomerase-i-inhibitorer med immunoterapi til behandlingen af kræft
US20180296561A1 (en) * 2015-10-07 2018-10-18 The University Of North Carolina At Chapel Hill The Methods For Treatment Of Tumors
KR20250079249A (ko) 2015-10-08 2025-06-04 마크로제닉스, 인크. 암 치료를 위한 조합 치료법
EP3362091A4 (en) * 2015-10-15 2019-04-24 Duke University COMBINATION THERAPY
SG11201803080YA (en) 2015-10-21 2018-05-30 Teclison Ltd Compositions and methods for immune-mediated cancer therapy
WO2017068349A1 (en) * 2015-10-23 2017-04-27 E-Therapeutics Plc Cannabinoid for use in immunotherapy
HRP20220436T1 (hr) * 2015-11-03 2022-05-27 Janssen Biotech, Inc. Protutijela koja se specifično vežu na pd-1 i njihove uporabe
JP6587756B2 (ja) * 2015-11-04 2019-10-09 デューク ユニバーシティー 免疫毒素およびチェックポイント阻害剤の併用療法
WO2017079747A1 (en) * 2015-11-06 2017-05-11 Regents Of The University Of Minnesota Activation of resident memory t cells for cancer immunotherapy
EP3371221A2 (en) * 2015-11-07 2018-09-12 MultiVir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
AU2016356708B2 (en) * 2015-11-20 2022-02-03 Memorial Sloan Kettering Cancer Center Methods and compositions for treating cancer
ES2913208T3 (es) * 2015-12-01 2022-06-01 Glaxosmithkline Ip Dev Ltd Tratamientos de combinación y usos y métodos de los mismos
AU2016364889B2 (en) 2015-12-02 2024-01-04 Agenus Inc. Antibodies and methods of use thereof
JP6906520B2 (ja) 2015-12-04 2021-07-21 シージェン インコーポレイテッド チェックポイント阻害剤と組みわせて２−デオキシ−２−フルオロ−ｌ−フコースを用いる癌治療
JP6958820B2 (ja) 2015-12-14 2021-11-02 エックス４ ファーマシューティカルズ， インコーポレイテッド がんを処置する方法
EP3389634B1 (en) 2015-12-14 2021-10-06 X4 Pharmaceuticals, Inc. Methods for treating cancer
BR112018012352A2 (pt) 2015-12-16 2018-12-11 Merck Sharp & Dohme Corp. anticorpos anti-lag3 e fragmentos de ligação ao antígeno
JP7055380B2 (ja) 2015-12-22 2022-04-18 エックス４ ファーマシューティカルズ， インコーポレイテッド 免疫不全疾患を処置するための方法
RU2748231C2 (ru) * 2016-01-08 2021-05-21 Момотаро-Джин Инк. Комбинированная терапия с использованием гена reic/dkk-3 и ингибитора контрольной точки иммунного ответа
WO2017120604A1 (en) * 2016-01-08 2017-07-13 Biothera, Inc. Beta-glucan immunotherapies affecting the immune microenvironment
WO2017120589A1 (en) * 2016-01-08 2017-07-13 Washington University Compositions comprising chemerin and methods of use thereof
US20210000921A1 (en) * 2016-01-11 2021-01-07 Flagship Pioneering Innovations V. Inc. Methods and compositions for modulating thymic function
CN108883132A (zh) * 2016-01-22 2018-11-23 X4 制药有限公司 用于治疗癌症的方法
GB201601868D0 (en) * 2016-02-02 2016-03-16 Lytix Biopharma As Methods
AU2017217426B2 (en) 2016-02-08 2022-12-01 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
JP6995061B2 (ja) * 2016-02-15 2022-02-04 トライゼル リミテッド 改善されたインターフェロン療法
AU2017222495B2 (en) 2016-02-23 2019-08-08 Biolinerx Ltd. Methods of treating acute myeloid leukemia
EP3213768A1 (en) * 2016-03-01 2017-09-06 LODOCO CLINICAL Kft Combination of low dose immune checkpoint blockade with high dose il-2 for treating metastatic cancer
GB201604213D0 (en) * 2016-03-11 2016-04-27 Proximagen Ltd Drug combination and its use in therapy
US20190343935A1 (en) * 2016-03-11 2019-11-14 University Of Louisville Research Foundation, Inc. Methods and compositions for treating tumors
WO2017167213A1 (en) * 2016-03-30 2017-10-05 Microbio Co., Ltd. Combined cancer therapy with immune checkpoint modulators and fermentation products by symbiotic microbiota
WO2017177230A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN116077439A (zh) 2016-04-29 2023-05-09 西奈山伊坎医学院 靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积
SG11201809541UA (en) * 2016-05-25 2018-12-28 Council Queensland Inst Medical Res Immune checkpoint inhibitors and cytotoxic t cells for the treatment of cancer
KR102366813B1 (ko) 2016-05-27 2022-02-24 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
SG11201810872UA (en) 2016-06-06 2019-01-30 Beyondspring Pharmaceuticals Inc Composition and method for reducing neutropenia
WO2017212021A1 (en) * 2016-06-10 2017-12-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancer
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
EP3808748A1 (en) 2016-06-21 2021-04-21 X4 Pharmaceuticals, Inc. Substituted piperidines as cxcr4-inhibitors
CA3027500A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
AU2017297506A1 (en) 2016-07-14 2019-02-21 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
WO2018014260A1 (en) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
JP7274214B2 (ja) 2016-08-02 2023-05-16 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫応答を調節するための生体材料
JP6995842B2 (ja) * 2016-08-25 2022-01-17 ナントミクス，エルエルシー 免疫療法マーカー及びその使用
JP7198666B2 (ja) * 2016-08-26 2023-01-04 哲治 奥野 微小血管血流低減剤およびその利用
US11406684B2 (en) * 2016-08-26 2022-08-09 Tetsuji Okuno Fine nano-sized medicinal agent and use thereof
EP3512499A4 (en) 2016-09-15 2020-08-05 Idera Pharmaceuticals, Inc. IMMUNODULATION WITH TLR9 AGONISTS FOR THE TREATMENT OF CANCER
CA3037253A1 (en) * 2016-09-26 2018-03-29 Advantagene, Inc. Methods of treating tim-3 elevation
CN118453850A (zh) * 2016-10-05 2024-08-09 弗罗里达中央大学研究基金会 涉及nk细胞和抗pdl1癌症治疗的方法和组合物
BR112019006504A2 (pt) 2016-10-06 2019-06-25 Pfizer Inc. regime de dosagem de avelumabe para o tratamento de câncer
CA3039071A1 (en) * 2016-10-07 2018-04-12 Secarna Pharmaceuticals Gmbh & Co. Kg Immunosuppression-reverting oligonucleotides inhibiting the expression of ido
CA3037380A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
WO2018071837A1 (en) * 2016-10-14 2018-04-19 Baylor College Of Medicine Radiofrequency field hyperthermia and solid tumor immunomodulation
WO2018075447A1 (en) * 2016-10-19 2018-04-26 The Trustees Of Columbia University In The City Of New York Combination of braf inhibitor, talimogene laherparepvec, and immune checkpoint inhibitor for use in the treatment cancer (melanoma)
EP3538152A4 (en) 2016-11-09 2020-09-30 Agenus Inc. ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE
IL307242A (en) 2016-12-07 2023-11-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
BR112019011582A2 (pt) 2016-12-07 2019-10-22 Agenus Inc. anticorpos e métodos de utilização dos mesmos
JP7125415B2 (ja) * 2016-12-09 2022-08-24 ジーンメディスン・カンパニー・リミテッド 細胞外基質分解因子を発現する組換えアデノウイルスを含む抗がん用組成物
WO2018107244A1 (en) * 2016-12-15 2018-06-21 Progen Pg500 Series Pty Ltd Composition and uses thereof
RU2761873C2 (ru) 2016-12-23 2021-12-13 Кэйо Юниверсити Композиции и способы для индукции cd8+ t-клеток
CN110431135A (zh) 2017-01-06 2019-11-08 大连万春布林医药有限公司 微管蛋白结合化合物及其治疗用途
KR20250159733A (ko) 2017-01-11 2025-11-11 브리스톨-마이어스 스큅 컴퍼니 Psgl-1 길항제 및 그의 용도
CN110381938A (zh) 2017-02-01 2019-10-25 大连万春布林医药有限公司 减少中性粒细胞缺乏症的方法
WO2018148183A1 (en) * 2017-02-07 2018-08-16 Memorial Sloan Kettering Cancer Center Use of immune checkpoint modulators in combination with antigen-specific t cells in adoptive immunotherapy
AU2018219862B2 (en) 2017-02-07 2020-09-17 Nant Holding IP, LLC Maximizing T-cell memory and compositions and methods therefor
KR102490278B1 (ko) * 2017-02-07 2023-01-18 각코우호우징 사이타마이카다이가쿠 암 면역요법의 임상 효과 예측을 위한 면역 바이오마커
US11815435B2 (en) 2017-02-24 2023-11-14 Hibercell, Inc. Beta glucan immunopharmacodynamics
EP3366703B1 (en) * 2017-02-28 2019-04-03 Ralf Kleef Immune checkpoint therapy with hyperthermia
CN119371510A (zh) * 2017-03-03 2025-01-28 特雷斯生物有限公司 肽疫苗
JP7148151B2 (ja) * 2017-03-08 2022-10-05 イェール ユニバーシティー 抗レナラーゼ抗体および抗ｐｄ－１抗体を用いる、がんを処置するための組成物および方法
MY200609A (en) 2017-03-14 2024-01-05 Five Prime Therapeutics Inc Antibodies binding to vista at acidic ph
CN107082812B (zh) * 2017-03-29 2018-11-13 上海科医联创生物科技有限公司 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
CN108728440A (zh) * 2017-04-25 2018-11-02 上海吉倍生物技术有限公司 Ctla-4基因的用途及相关药物
UY37695A (es) * 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
GB2562721A (en) * 2017-05-16 2018-11-28 Fastbase Solutions Ltd Kits, methods and their uses for detecting cell-cell interactions in a sample
JP2020522486A (ja) * 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
WO2019011879A1 (en) * 2017-07-09 2019-01-17 Rainer Henning THERAPEUTIC AGENT FOR THE TREATMENT OF CAPILLARY LEAK SYNDROME
EP3658914A1 (en) 2017-07-28 2020-06-03 Bristol-Myers Squibb Company Predictive peripheral blood biomarker for checkpoint inhibitors
EP3661550A4 (en) 2017-08-03 2021-08-04 Regents of the University of Minnesota ACTIVATION OF LYMPHOCYTES T MEMORY RESIDENTS FOR THE TREATMENT OF CANCER
AU2018317390A1 (en) * 2017-08-14 2020-04-02 Cytodigm, Inc. Microparticle formulations of adenosine receptor antagonists for treating cancer
PE20200797A1 (es) 2017-08-25 2020-08-10 Five Prime Therapeutics Inc Anticuerpos que se unen especificamente a b7-h4 humana
JP7236385B2 (ja) * 2017-09-26 2023-03-09 中外製薬株式会社 医薬組成物
KR20200064112A (ko) 2017-10-03 2020-06-05 크리티테크, 인크. 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달
SG11202003625VA (en) 2017-11-03 2020-05-28 Aurigene Discovery Tech Ltd Dual inhibitors of tim-3 and pd-1 pathways
CN111386128A (zh) 2017-11-06 2020-07-07 奥瑞基尼探索技术有限公司 用于免疫调节的联合疗法
EP3713548A4 (en) * 2017-11-21 2021-06-23 Icahn School of Medicine at Mount Sinai Promoting trained immunity with therapeutic nanobiologic compositions
WO2019122941A1 (en) * 2017-12-21 2019-06-27 Debiopharm International Sa Combination anti cancer therapy with an iap antagonist and an anti pd-1 molecule
CN117050184A (zh) 2017-12-28 2023-11-14 南京传奇生物科技有限公司 针对tigit的单域抗体和其变体
CN111655272A (zh) * 2018-01-09 2020-09-11 中天生物科技股份有限公司 活化肿瘤浸润淋巴细胞(TILs)的方法
KR20250114571A (ko) 2018-01-15 2025-07-29 난징 레전드 바이오테크 씨오., 엘티디. Pd-1에 대한 단일-도메인 항체 및 이의 변이체
CA3089226A1 (en) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
US11542259B2 (en) 2018-01-26 2023-01-03 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
CA3088198A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
BR112020015199A2 (pt) 2018-01-26 2021-05-04 Exelixis, Inc. compostos para o tratamento de distúrbios dependentes de quinase
WO2019152680A1 (en) * 2018-01-31 2019-08-08 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating cancer using chrna6 inhibitors
CA3089781A1 (en) 2018-02-02 2019-08-08 Murray & Poole Enterprises, Ltd Use of colchicine to inhibit tumor growth and metastases
JP2021512638A (ja) * 2018-02-09 2021-05-20 学校法人慶應義塾 Ｃｄ８＋ｔ細胞の誘導のための組成物および方法
WO2019165077A1 (en) 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody formulations
EP3758735B1 (en) 2018-02-28 2023-12-13 AP Biosciences, Inc. Bifunctional proteins combining checkpoint blockade for targeted therapy
KR20200144094A (ko) 2018-03-02 2020-12-28 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 및 이의 사용 방법
EA202091773A1 (ru) 2018-03-14 2021-06-22 Ориджен Дискавери Текнолоджис Лимитед Способ модуляции сигнальных путей tigit и pd-1 с применением 1,2,4-оксадиазольных соединений
AU2019322487B2 (en) 2018-03-19 2024-04-18 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
AU2019239747A1 (en) 2018-03-21 2020-10-08 Bristol-Myers Squibb Company Antibodies binding to VISTA at acidic pH
WO2019183924A1 (en) 2018-03-30 2019-10-03 Syz Cell Therapy Co. Improved multiple antigen specific cell therapy methods
EP3773591A4 (en) 2018-04-05 2021-12-22 Sumitomo Dainippon Pharma Oncology, Inc. AXL KINASE INHIBITORS AND THEIR USE
WO2019195759A1 (en) * 2018-04-05 2019-10-10 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer
US11564980B2 (en) 2018-04-23 2023-01-31 Nantcell, Inc. Tumor treatment method with an individualized peptide vaccine
TWI816603B (zh) 2018-04-23 2023-09-21 美商南特細胞公司 新抗原表位疫苗及免疫刺激組合物及方法
EP3566718A1 (en) 2018-05-07 2019-11-13 Universitätsmedizin der Johannes Gutenberg-Universität Mainz A pharmazeutical combination (treg depleting agent, checkpoint inhibitor, tlr9 agonist) for use in the treatment of cancer
MX2020012939A (es) 2018-05-31 2021-02-15 Ono Pharmaceutical Co Biomarcadores para determinar la eficacia de los inhibidores de puntos de control inmunitarios.
IL278740B2 (en) * 2018-06-01 2024-01-01 Eisai R&D Man Co Ltd Methods for using splicing modulators
US20210186978A1 (en) * 2018-06-01 2021-06-24 Tarveda Therapeutics, Inc. Combination therapy
WO2019236857A1 (en) * 2018-06-08 2019-12-12 Harrow Health, Inc. Pyrimethamine-based pharmaceutical compositions and methods for fabricating thereof
US11266615B2 (en) 2018-06-08 2022-03-08 Harrow Ip, Llc Pyrimethamine-based pharmaceutical compositions and methods for fabricating thereof
US20190380998A1 (en) * 2018-06-15 2019-12-19 The Board Of Regents Of The University Of Texas System Methods of treating and preventing melanoma with s-equol
WO2019240871A1 (en) 2018-06-15 2019-12-19 The Board Of Regents Of The University Of Texas System Methods of treating and preventing breast cancer with s-equol
GB201810058D0 (en) * 2018-06-19 2018-08-08 Cytovation As Combination therapy using a peptide
BR112021000303A2 (pt) 2018-07-11 2021-04-13 Five Prime Therapeutics, Inc. Anticorpos que se ligam a vista em ph ácido
EP3836964A1 (en) * 2018-08-15 2021-06-23 University of Florida Research Foundation, Inc. Methods of sensitizing tumors to treatment with immune checkpoint inhibitors
US20210309744A1 (en) * 2018-08-29 2021-10-07 Shattuck Labs, Inc. Combination therapies comprising pd-1-based chimeric proteins
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
US20220047703A1 (en) * 2018-09-24 2022-02-17 BioVaxys Inc. Bihaptenized autologous vaccines and uses thereof
US12257286B2 (en) 2018-10-31 2025-03-25 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2020092589A1 (en) * 2018-10-31 2020-05-07 Nantomics, Llc Immune checkpoint therapeutic methods
EP3873500A4 (en) 2018-10-31 2023-01-11 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
WO2020091944A1 (en) * 2018-10-31 2020-05-07 Nantomics, Llc Genomic and immune infiltration differences between msi and mss gi tumors
SG11202104923YA (en) * 2018-11-16 2021-06-29 Arqule Inc Pharmaceutical combination for treatment of cancer
JP2022512384A (ja) * 2018-12-13 2022-02-03 ロード アイランド ホスピタル Ａｓｐｈ発現腫瘍の成長および進行の阻害
US20230071889A1 (en) * 2018-12-21 2023-03-09 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
WO2020163628A1 (en) 2019-02-06 2020-08-13 Cornell University Darc expression as prognosticator of immunotherapy outcomes
WO2020163569A1 (en) * 2019-02-08 2020-08-13 H. Lee Moffitt Cancer Center And Research Institute Inc. Sirt2-ablated chimeric t cells
EP3928792A4 (en) 2019-02-20 2022-12-14 Saitama Medical University BIOMARKERS IN PERIPHERAL BLOOD FOR ASSESSING THE ANTI-TUMORS IMMUNE EFFECT OF RADIATION THERAPY
CN113473989B (zh) * 2019-02-27 2024-03-08 武田药品工业株式会社 Sumo活化酶抑制剂和检查点抑制剂的施用
CN109771445B (zh) * 2019-03-20 2022-08-05 青岛东海药业有限公司 酪酸梭菌在制备诱导抗肿瘤免疫及免疫检查点抑制剂增敏制剂中的应用
CN111751545A (zh) * 2019-03-28 2020-10-09 中国科学院上海药物研究所 一种筛选pd-l1/pd-1检测点抑制剂的方法
JP7713390B2 (ja) * 2019-04-03 2025-07-25 ターグイミューン セラピューティクス アクチエンゲゼルシャフト がん治療のための免疫療法
EP3721899A1 (en) * 2019-04-08 2020-10-14 China Medical University Combination therapies comprising dendritic cells-based vaccine and immune checkpoint inhibitor
US20220202818A1 (en) 2019-04-18 2022-06-30 The Regents Of The University Of Michigan Combination with checkpoint inhibitors to treat cancer
WO2020246846A1 (ko) * 2019-06-05 2020-12-10 연세대학교 산학협력단 Tox에 기초한 면역 항암 요법에 대한 치료 반응 예측 방법
US12308095B1 (en) 2019-06-11 2025-05-20 Nantbio, Inc. Prediction of computational pathway circuits
US20220370562A1 (en) * 2019-06-30 2022-11-24 Memorial Sloan Kettering Cancer Center Methods and compositions for treatment of pancreatic cancer
US11364291B1 (en) 2019-07-18 2022-06-21 Nantcell, Inc. Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer
US20220305038A1 (en) * 2019-08-16 2022-09-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
TWI776276B (zh) * 2019-11-13 2022-09-01 中國醫藥大學 異種組織細胞組合物治療癌症之用途
JP7630507B2 (ja) 2019-11-18 2025-02-17 ヤンセン バイオテツク，インコーポレーテツド 変異型ｃａｌｒ及びｊａｋ２に基づくワクチン並びにこれらの使用
KR20220137007A (ko) * 2020-01-02 2022-10-11 머크 샤프 앤드 돔 엘엘씨 Pd-1 길항제, ilt4 길항제 및 렌바티닙 또는 그의 염을 사용하는 조합 암 치료
JP2023515675A (ja) * 2020-03-05 2023-04-13 メルク・シャープ・アンド・ドーム・エルエルシー Ｐｄ－１アンタゴニスト、ｃｔｌａ４アンタゴニストおよびレンバチニブまたはその薬学的に許容される塩の組合せを用いる癌を治療する方法
JP2023517956A (ja) 2020-03-10 2023-04-27 エックス４ ファーマシューティカルズ， インコーポレイテッド 好中球減少症を処置する方法
JP2023517534A (ja) * 2020-03-18 2023-04-26 ジーアイ・イノベイション・インコーポレイテッド Ｉｌ－２タンパク質およびｃｄ８０タンパク質を含む融合タンパク質および抗癌剤を含む癌治療用薬学組成物
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022198101A1 (en) 2021-03-19 2022-09-22 Trained Therapeutix Discovery, Inc. Compounds for regulating trained immunity, and their methods of use
EP4319751A4 (en) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS
JP7018531B1 (ja) 2021-04-30 2022-02-10 潤 齋藤 Ａｘｌ阻害剤
EP4445914A4 (en) * 2021-12-10 2025-11-26 Inxmed Nanjing Co Ltd PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMORS AND USE
JP2025087939A (ja) * 2022-04-13 2025-06-11 アステラス製薬株式会社 がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｔｓｐａｎ８－抗ｃｄ３二重特異性抗体の使用
WO2023203561A1 (en) * 2022-04-19 2023-10-26 Enlivex Therapeutics Rdo Ltd Apoptotic cell - check point inhibitor combination therapy
CN117050177B (zh) * 2023-08-25 2024-03-08 遵义北科融汇生命科技有限公司 血液分离的免疫细胞联合药物治疗癌症的用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
AU772676B2 (en) 1998-12-23 2004-05-06 Amgen Fremont Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
AU784012B2 (en) 1999-08-24 2006-01-12 E. R. Squibb & Sons, L.L.C. Human CTLA-4 antibodies and their uses
WO2001054732A1 (en) 2000-01-27 2001-08-02 Genetics Institute, Llc. Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
US7452535B2 (en) * 2002-04-12 2008-11-18 Medarex, Inc. Methods of treatment using CTLA-4 antibodies
CN101928344B (zh) 2002-10-17 2014-08-13 根马布股份公司 抗cd20的人单克隆抗体
AU2003293411B2 (en) 2002-12-06 2010-10-28 Northwest Biotherapeutics, Inc. Administration of dendritic cells partially matured in vitro for the treatment of tumors
GB0406598D0 (en) * 2004-03-24 2004-04-28 Univ Leicester Vaccine
JP4361545B2 (ja) * 2005-05-09 2009-11-11 小野薬品工業株式会社 ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
NZ582150A (en) * 2007-06-18 2012-08-31 Msd Oss Bv Antibodies to human programmed death receptor pd-1
GB0920258D0 (en) * 2009-11-19 2010-01-06 Alligator Bioscience Ab New medical agents and use thereof
PT2691112T (pt) * 2011-03-31 2018-07-10 Merck Sharp & Dohme Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
US9132281B2 (en) * 2011-06-21 2015-09-15 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
SG10201700698WA (en) * 2012-05-15 2017-02-27 Bristol Myers Squibb Co Cancer immunotherapy by disrupting pd-1/pd-l1 signaling

Also Published As

Publication number Publication date
EP3065772B1 (en) 2024-07-24
US20240382572A1 (en) 2024-11-21
JP2016540042A (ja) 2016-12-22
EP4461372A2 (en) 2024-11-13
EA201690912A1 (ru) 2016-10-31
BR112016010224A2 (pt) 2018-05-02
EP4461372A3 (en) 2025-01-22
MX2022006726A (es) 2022-06-09
IL318946A (en) 2025-04-01
IL292510A (en) 2022-06-01
ES2991853T3 (es) 2024-12-05
PH12016500841A1 (en) 2016-07-04
US20240358807A1 (en) 2024-10-31
MX2016005925A (es) 2016-11-28
HK1232119A1 (zh) 2018-01-05
KR20160093012A (ko) 2016-08-05
CA2929407A1 (en) 2015-05-14
WO2015069770A1 (en) 2015-05-14
CN105828834A (zh) 2016-08-03
EP3065772A4 (en) 2017-09-13
US20150273033A1 (en) 2015-10-01
IL245337B (en) 2022-05-01
EP3065772A1 (en) 2016-09-14
IL245337A0 (en) 2016-06-30
US20150202291A1 (en) 2015-07-23

Similar Documents

Publication Publication Date Title
US20240358807A1 (en) Combinations of checkpoint inhibitors and therapeutics to treat cancer
EP3057990B1 (en) Compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
JP2020114837A (ja) 細胞免疫療法前の細胞毒性プレコンディショニングの代替
US20230414540A1 (en) Combination of immunotherapy with local chemotherapy for the treatment of malignancies
JP2018530624A (ja) 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法
AU2018265534A1 (en) Anti-EGFR/high affinity NK-cells compositions and methods for chordoma treatment
TW202327610A (zh) 具有檢查點抑制劑抗性或抗性易感性之晚期性/轉移性癌症之改良治療
WO2018039332A1 (en) Immunoswitch nanoparticles for reprogrammed t cell responses
AU2014331728A1 (en) Methods and compositions for regulatory T-cell ablation
US20220265792A1 (en) Methods for treating solid tumors
JP2025531789A (ja) がん治療のためのｓｈｐ－１阻害剤
US11897950B2 (en) Osteopontin monoclonal antibodies
JP2024519449A (ja) がん治療における使用のための抗ガレクチン－９抗体と化学療法剤との併用
JP7407452B2 (ja) がんの治療及び／又は予防のための医薬
US20220047701A1 (en) Combination of her2/neu antibody with heme for treating cancer
US20230255978A1 (en) Methods for treating glioblastoma
WO2023203561A1 (en) Apoptotic cell - check point inhibitor combination therapy
NZ750663A (en) Compositions and methods for cancer immunotherapy
NZ750663B2 (en) Compositions and methods for cancer immunotherapy
HK1255016B (zh) 通过组合疗法治疗实体或淋巴肿瘤的方法
HK1227888A1 (en) Compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
HK1227888B (en) Compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application